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Objective/Background: Sleep abnormalities are characteristic of chronic fatigue syndrome (CFS, also
known as ‘ME’), however it is unknown whether sleep might be a causal risk factor for CFS/ME.
Patients/Methods: We analysed data from the Avon Longitudinal Study of Parents and Children (ALSPAC)
birth cohort. We describe sleep patterns of children aged 6 months to 11 years, who were subsequently
classiﬁed as having (or not having) ‘chronic disabling fatigue’ (CDF, a proxy for CFS/ME) between the ages
13 and 18 years, and we investigated the associations of sleep duration at age nine years with CDF at age
13 years, as well as sleep duration at age 11 years with CDF at age 16 years.
Results: Children who had CDF during adolescence had shorter night-time sleep duration from 6 months
to 11 years of age, and there was strong evidence that difﬁculties in going to sleep were more common in
children who subsequently developed CDF. The odds of CDF at age 13 years were 39% lower (odds ratio
(OR) ¼ 0.61, 95% CI ¼ 0.43, 0.88) for each additional hour of night-time sleep at age nine years, and the
odds of CDF at age 16 years were 51% lower (OR ¼ 0.49, 95% CI ¼ 0.34, 0.70) for each additional hour of
night-time sleep at age 11 years. Mean night-time sleep duration at age nine years was 13.9 (95%
CI ¼ 3.75, 24.0) minutes shorter among children who developed CDF at age 13 years, and sleep duration
at age 11 years was 18.7 (95% CI ¼ 9.08, 28.4) minutes shorter among children who developed CDF at age
16 (compared with children who did not develop CDF at 13 and 16 years, respectively).
Conclusions: Children who develop chronic disabling fatigue in adolescence have shorter night-time
sleep duration throughout early childhood, suggesting that sleep abnormalities may have a causal
role in CFS/ME or that sleep abnormalities and CFS/ME are associated with a common pathophysio-
logical cause.
© 2018 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Background
Chronic fatigue syndrome (CFS, also known as Myalgic
encephalomyelitis [ME]) in children and young people is a debili-
tating disease with an adverse effect on the lives of children and
their families [1e3]. The UK National Institute for Health and Care
Excellence (NICE) guidelines state that diagnosis of CFS/ME should
bemade after threemonths of persistent or recurrent fatigue that islescent Health, University of
BN, UK.
awley).
ier B.V. This is an open access articnot the result of ongoing exertion, not substantially alleviated by
rest, has resulted in a substantial reduction in activities, has no
other known cause and is accompanied by one or more of ten
typical symptoms [4]. The widely used CDC/Fukuda diagnostic
criteria require six months’ duration of fatigue and the presence of
four of eight typical symptoms [5]. Both criteria specify disturbed or
unrefreshing sleep as one of the typical symptoms of CFS/ME, and
this symptom has been recorded in 95e97% of adult and adolescent
(age 12e18 years) patients [6,7] and in 85% of paediatric patients
under 12 years of age [6].
Whilst abnormal sleep is part of the clinical picture of CFS/ME
[8], and a major feature of the lived experience of adult [9]le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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associate sleep dysfunction with CFS/ME have not been substanti-
ated. These include sleep abnormalities and CFS/ME sharing a
common cause (physiological, neurological, etc.), CFS/ME precipi-
tating or perpetuating sleep dysfunction or vice versa, or abnormal
sleep in patients with CFS/ME being a symptom of common CFS/
ME-related comorbidities such as low mood and chronic pain [8].
Birth cohort data from the Avon Longitudinal Study of Parents
and Children (ALSPAC) have been used to describe childhood sleep
patterns from 6 months to 11 years [11] of age and to estimate the
prevalence of ‘chronic disabling fatigue’ (CDF, a proxy for clinically
diagnosed CFS/ME) at ages 13, 16 and 18 years [12e14]. In the
present study, we describe sleep patterns in children who were
subsequently classiﬁed as having (or not having) CDF, and we
investigate possible associations of sleep at age nine years with CDF
at age 13 years and sleep at age 11 years with CDF at age 16 years.
2. Methods
2.1. Study cohort
ALSPAC is a population-based study that aims to investigate a
wide range of inﬂuences on the health and development of children
[15]. Pregnant women residing in the former Avon Health Authority
in South West England, who had an estimated date of delivery be-
tween 1 April 1991 and 31 December 1992, were invited to partici-
pate, which resulted in a cohort of 14,541 pregnancies and 13,978
children alive at 12 months of age (excluding triplets and quadru-
plets). The primary source of data for the present study was parent-
completed questionnaires administered at four time points during
the antenatal period and at regular intervals following birth. The
ALSPAC study website contains details of all the data that are avail-
able through a fully searchable data dictionary (www.bris.ac.uk/
alspac/researchers/data-access/data-dictionary/). Ethical approval
for the study was obtained from the ALSPAC Ethics and Law Com-
mittee (IRB00003312) and the local research ethics committees.
2.2. Classiﬁcation of CFS/ME
We use the term ‘chronic disabling fatigue’ (CDF) rather than
CFS/ME because children in our study were not examined by a
physician. Children were classiﬁed as having CDF (of >6 months’
duration) based on information provided by parents at age 13 years
[12], by parents and children at age 16 years [13] and by children at
age 18 years [14]. CDF at ages 13 and 16 years was deﬁned as fatigue
(feeling tired or lacking in energy) of >6 months’ duration that was
associated with absence from full-time school or that had pre-
vented the child from taking part in activities ‘quite a lot’ or ‘a great
deal’, excluding fatigue possibly associated with sport, snoring, and
other illnesses [12]. At age 16 years, children could only be classi-
ﬁed as having CDF if they scored 19 (of 33) on the Chalder Fatigue
scale [16,17]. Teenagers completed the Revised Clinical Interview
Schedule (CIS-R) [18] at age 18 years and were classiﬁed as having
CDF if they had been getting tired or had been lacking in energy
during the past month and then responded ‘yes’ to >2 of the
following four items: (1) felt tired or lacking in energy for four days
or more in the past seven days; (2) felt tired or lacking in energy for
more than three hours in total on any day in the past seven days; (3)
felt so tired or lacking in energy that they had to push themselves to
get things done on one or more occasion in the past seven days and
(4) felt tired or lacking in energy when doing things they enjoy in
the past seven days. Teenagers were not classiﬁed as having CDF if
the tiredness or lack of energy had lasted for <6 months or was
caused by exercise or medication or if the teenager felt better after
resting or did not feel exhausted the day after exercising. Childrenwho met CDF criteria at age 16 or 18 years but who were reported
by parents to have had problems with alcohol or drugs (crack,
solvents, heroin or cocaine) or were diagnosed to have anorexia
nervosa were classiﬁed as not having CDF. According to our deﬁ-
nitions, the prevalence of CDF of >6 months’ duration at age 13, 16
and 18 years was 1.13% (76/6720), 1.46% (84/5756) and 2.40% (103/
4290), respectively [14] (Fig. 1). Our deﬁnitions of CDF at each age
did not exclude children who had comorbid depressive symptoms.
Approximately 30% of the children with CFS/ME in specialist ser-
vices have comorbid depression, and it is unclear whether comor-
bid depressive symptoms are predictive of, or secondary to, CFS/ME
[19]. Therefore, we think it would be unreasonable to reclassify or
exclude all children with CDF and comorbid depression, and this
would also substantially reduce the study power (halving the
prevalence of CDF at some age points). In ALSPAC, high levels of
comorbid depressive symptoms in children with CDF at ages 13, 16
and 18 years can be deﬁned using the scores of the Short Mood and
Feelings Questionnaire (SMFQ) with a threshold 11 [20]. The
proportions of children with CDF at age 16 and 18 years who would
be excluded from our analysis because of missing SMFQ data were
56% (47/84) and 51.5% (53/103), respectively. Furthermore, of chil-
dren with CDF who had SMFQ data, 15.8% (12/76) at age 13 years,
60% (21/35) at age 16 years and 40% (20/50) at age 18 years had
scores 11. Reclassifying these children as not having CDF (or
excluding them from our analysis) would result in only 64, 14 and
30 children with CDF at ages 13, 16 and 18 years, respectively.
2.3. Sleep measurements
Maternal reports of infant and child sleep at ages 6, 18, 30, 42,
69, 81, 115 and 140 months follow-up time points were collected
using postal questionnaires [11]. Most questionnaires were
returned within the ﬁrst few weeks after being sent out, but some
allowance was made for slow responses, with windows of 5e12,
18e24, 29e25, 41e47, 68e75, 80e88, 114e122 and 137e147
months for the ages 6, 18, 30, 42, 69, 81, 115 and 140 months’ time
points, respectively. Night-time sleep duration was calculated from
questions asking what time (to the nearest minute) the infant or
child “normally” went to sleep in the evening (bedtime) and woke
up in themorning (waking time). Daytime sleep duration (up to age
seven years), the number of night-time awakenings (up to age nine
years, in response to ‘How often during the night does he/she
usually wake?’) and difﬁculty going to sleep (from age 18months to
9 years, in response to ‘In the past year has your had difﬁculty going
to sleep?’) were also recorded. Among children who were not
subsequently classiﬁed as having CDF at any of the three time
points (n ¼ 7824), availability of sleep data declined from 93% at
age six months to 80% at age 11 years; among children classiﬁed as
having CDF (n¼ 242), availability of sleep data declined from 96% at
age six months to 86% at age 11 years (Supplementary Table 1).
2.4. Statistical analysis
2.4.1. Sleep patterns from the age of 6 months to 11 years in
association with CDF during adolescence
We calculatedmean (95% CI) night-time, daytime and total sleep
durations and mean bedtime and waking time at each follow-up
time point, ie at age 6, 18, 30, 42, 69, 81, 115 and 140 months,
among two groups of children: those who were classiﬁed as having
CDF during adolescence (age 13,16 or 18 years) and thosewhowere
not. We tabulated the number of night-time awakenings (as 0, 1 or
2þ) and difﬁculties going to sleep (as responses ‘No, did not
happen’, ‘Yes, but did not worry me’) ‘Yes, worried me a bit and Yes,
worried me greatly’). We used a nonparametric test for trend over
time (from age six months to nine years) in the number of night-
Fig. 1. Flowchart of Avon Longitudinal Study of Parents and Children (ALSPAC) participants who provided exposure and outcome data for this study.
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two outcomes as binary variables (night-time awakenings ¼ 0 or
1þ; difﬁculty going to sleep ¼ Yes or No) to calculate odds ratios
comparing the two groups of children (No CDF, CDF) adjusted for
sex and age (at each follow-up time point). We used likelihood
ratios to test whether effects of night-time awakening or difﬁculty
going to sleep on the odds of developing CDF changed over time.
We estimated the overall mean difference in bedtime and waking
times (in minutes) using linear regression adjusted for sex and age
(at each follow-up time point).
2.4.2. Association of sleep with CDF adjusted for potential
confounders
We conducted two separate analyses to investigate possible
causal relationships between sleep duration at age nine years with
CDF at age 13 years and between sleep duration at age 11 years with
CDF at age 16 years. We did not have a suitable proximal measure of
sleep duration to investigate a causal relationship between sleep
duration and CDF at age 18 years. We also estimated (using linear
regression) the mean difference in night-time sleep duration at 9
and 11 years of age comparing children who did or did not develop
CDF at age 13 and 16 years, respectively.
2.4.2.1. Outcomes. The outcomes of the analyses were CDF at age 13
years (median 13.1 (IQR 13.1e13.2) years) and CDF at age 16 years.CDF at age 16 years was based on parental questionnaire data
(median age 16.6 (IQR 16.5e16.8) years) and child questionnaire
data (median age 16.7 (IQR 16.5e17.1) years). To avoid possible
overlap between primary exposures and outcomes in our causal
analyses, we excluded childrenwith >5 years’ duration of fatigue at
age 13 (10 of 76 children) and 16 (11 of 84 children) years. After
these exclusions, 66/6720 children at age 13 years and 73/5756
children at age 16 years were classiﬁed as having CDF for causal
analyses (Fig. 1).
2.4.2.2. Primary exposures. The primary exposure for CDF at age 13
years was duration of night-time sleep at age nine years (median
9.7 years). The primary exposure for CDF at age 16 years was
duration of night-time sleep at age 11 years (median 11.7 years).
2.4.2.3. Other variables. A set of putative risk factors for paediatric
CFS/ME were identiﬁed based on our earlier work [12e14,21] and a
review of the literature. To identify possible associations between
our exposures and outcome, we identiﬁed confounding variables
that could potentially bias any observed association. We stipulated
that exposures related to CDF at age 13 years must have been
collected at or before age nine years. This was to prevent any
overlap between outcome and exposure, thereby removing the
possibility of reverse causality. For CDF at age 16 years, the exposure
cut-off age was 11 years.
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with experts in the ﬁelds related to the primary and other expo-
sures (sleep, physical activity, and child and maternal psychopa-
thology) and specialists in paediatric CFS/ME. Consensus from
these meetings was encapsulated in the form of directed acyclic
graphs (DAGs). DAGs are causal diagrams which provide a method
for formalising and clarifying relationships between variables [22],
thereby informing the process of building causal models [23]. DAGs
are useful for identifying variables that confound the relationship
between two variables, thus providing researchers with a set of
variables for which adjustment is necessary (or unnecessary) to
obtain unbiased estimates of the association between two variables
[24]. We refer to the ﬁnal (logistic regression) model comprising
the outcome (CDF as a binary variable), the primary exposure (sleep
duration as a continuous variable) and all the identiﬁed con-
founders as the ‘analysis model’.2.4.2.4. Missing data and multiple imputation. If the analysis model
is ﬁtted to a ‘complete case’ dataset, ie dropping participants who
have missing data for any of the variables in the model, standard
errors will be inﬂated and bias may arise. If missingness is
dependent only on observed data, ie data in the analysis model are
‘missing at random’ (MAR), then multiple imputations can be used
to correct this bias. Multiple imputation uses a model based on the
analysis model plus auxiliary variables which are selected because
of the following: (a) they are associated with themissing variables;
(b) they are associated with the missingness of the missing vari-
ables and (c) they do not have too much missing data (to ensure
stable imputation models which therefore produce reliable
estimates).
The number of imputations required to achieve convergence
of parameter estimates was determined by checking the estimate
of the Monte Carlo error (MCE) in relation to the standard error of
the coefﬁcient being estimated. The number of imputations was
increased until MCE reached a value which was <10% of theTable 1
Childhood sleep durations in children with and without chronic disabling fatigue during
Children without CDF
hours (95% CI)
Night-time sleep duration
6 months 10.79 (10.76, 10.82)
18 months 11.32 (11.30, 11.35)
30 months 11.22 (11.20, 11.25)
42 months 11.26 (11.24, 11.28)
69 months 11.29 (11.27, 11.30)
81 months 11.14 (11.12, 11.15)
115 months 10.46 (10.44, 10.47)
140 months 9.82 (9.81, 9.84)
Daytime sleep duration
6 months 2.358 (2.334, 2.383)
18 months 1.447 (1.434, 1.459)
30 months 0.716 (0.699, 0.734)
42 months 0.239 (0.227, 0.252)
69 months 0.014 (0.011, 0.018)
81 months 0.007 (0.005, 0.010)
Total sleep duration
6 months 13.15 (13.11, 13.19)
18 months 12.77 (12.74, 12.80)
30 months 11.94 (11.91, 11.97)
42 months 11.50 (11.48, 11.52)
69 months 11.30 (11.28, 11.32)
81 months 11.14 (11.13, 11.16)
115 months 10.45 (10.44, 10.47)
140 months 9.82 (9.81, 9.84)
a Based on raw (non-imputed) data e see Supplementary Table 1 for number of obser
b Student t test.standard error of the estimate. The sample size after imputation
was N ¼ 13,978, representing children in the ‘core’ ALSPAC sample
who were alive at age one year and who were either a singleton or
twin. Multivariable imputationwas performed using an imputation
sampling method [25], which incorporates all sources of variability
and uncertainty in the imputed values. The analysis model is then
ﬁtted to the imputed datasets, using Rubin’s rules to combine the
estimates into a single estimate that is unbiased (or less biased) by
differential losses to follow-up [26].3. Results
3.1. Sleep patterns from age 6 months to 11 years
The total number of children classiﬁed with CDF during
adolescence was 242, of whom 223 (92.2%) had CDF at only one
time point (63 at age 13 years, 67 at age 16 years and 93 at age 18
years) and 19 (7.9%) had CDF at 1 þ time points. Children who had
CDF during adolescence had shorter night-time sleep duration from
age 6 months to 11 years (Table 1, Fig. 2). There were no differences
in daytime sleep duration (Table 1, Fig. 3), and the differences in
total sleep duration (Table 1, Fig. 4) were attributable to differences
in night-time sleep.
In both groups, the number of night-time awakenings
decreased as the child grew older (non-parametric test for trend,
p < 0.001). There was some evidence that children who devel-
oped CDF had more night-time awakenings at ages six months
and six, seven and nine years (Fig. 5, Table 2). Overall, the odds of
developing CDF were 33% higher among children who had one or
more night-time awakenings (odds ratio (OR) ¼ 1.33 (95% CI
1.19e1.49) adjusted for sex and age), and this odds ratio was
constant over time (likelihood ratio test for interaction between
CDF and time, p ¼ 0.75).
Difﬁculties going to sleep increased in both groups as the child
grew older (non-parametric test for trend, p < 0.001). There wasadolescence (age 13, 16 or 18 years).a
Children with CDF Mean difference (95% CI)b
hours (95% CI) minutes (95% CI)
10.64 (10.48, 10.81) 8.86 (19.2, þ1.52), p ¼ 0.09
11.18 (11.05, 11.32) 8.25 (16.4, 0.08), p ¼ 0.05
11.14 (11.01, 11.28) 4.86 (12.9, þ3.17), p ¼ 0.24
11.16 (11.04, 11.27) 6.18 (13.1, þ0.78), p ¼ 0.08
11.18 (11.08, 11.28) 6.60 (12.2, 0.98), p ¼ 0.02
11.02 (10.94, 11.11) 6.90 (12.2, 1.62), p ¼ 0.01
10.31 (10.22, 10.40) 8.98 (14.3, 3.62), p ¼ 0.001
9.61 (9.51, 9.72) 12.7 (18.0, 7.47), p < 0.001
2.401 (2.264, 2.539) þ2.57 (5.72, þ10.9), p ¼ 0.54
1.469 (1.404, 1.535) þ1.36 (2.80, þ5.52), p ¼ 0.52
0.693 (0.595, 0.792) 1.38 (7.39, þ4.63), p ¼ 0.65
0.178 (0.119, 0.238) 3.65 (7.86, þ0.56), p ¼ 0.09
0.014 (0.009, 0.037) 0.02 (1.21, þ1.17), p ¼ 0.97
0.000 (0.000, 0.000) 0.44 (1.33, þ0.45), p ¼ 0.34
13.04 (12.83, 13.26) 6.30 (19.3, þ6.67), p ¼ 0.34
12.65 (12.50, 12.81) 6.89 (16.1, þ2.32), p ¼ 0.14
11.84 (11.70, 11.97) 6.23 (14.9, þ2.42), p ¼ 0.16
11.33 (11.22, 11.45) 9.83 (17.1, 2.56), p ¼ 0.008
11.19 (11.09, 11.29) 6.62 (12.3, 0.92), p ¼ 0.02
11.02 (10.94, 11.11) 7.34 (12.7, 2.01), p ¼ 0.007
10.31 (10.22, 10.40) 8.98 (14.3, 3.62), p ¼ 0.001
9.61 (9.51, 9.72) 12.7 (18.0, 7.47), p < 0.001
vations at each age.
Fig. 3. Mean daytime sleep duration at age 6e81 months among children who did or did not develop chronic disabling fatigue (CDF) at age 13, 16 or 18 years (vertical bars indicate
95% CI).
Fig. 2. Mean night-time sleep duration at age 6e140 months among children who did or did not develop chronic disabling fatigue (CDF) at age 13, 16 or 18 years (vertical bars
indicate 95% CI).
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Fig. 4. Mean total sleep duration at age 6e140 months among children who did or did not develop chronic disabling fatigue (CDF) at age 13, 16 or 18 years (vertical bars indicate 95% CI).
Fig. 5. Number of night-time awakenings at age 6e115 months among children who did or did not develop chronic disabling fatigue (CDF) at age 13, 16 or 18 years (vertical bars
indicate 95% CI).
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Table 2
Childhood night-time awakenings and difﬁculty in sleeping in children with and without chronic disabling fatigue at age 13, 16 or 18 years.
Children without CDF Children with CDF P-valuea
Number of night-time awakenings Number of night-time awakenings
n 0 1 2þ n 0 1 2þ
6 months 7270 5574 (76.7%) 460 (6.33%) 1236 (17.0%) 233 165 (70.8%) 13 (5.58%) 55 (23.6%) 0.03
18 months 7168 3682 (51.4%) 2147 (30.0%) 1339 (18.7%) 230 106 (46.1%) 72 (31.3%) 52 (22.6%) 0.20
30 months 6967 3521 (50.5%) 2319 (33.3%) 1127 (16.2%) 218 103 (47.3%) 78 (35.8%) 37 (17.0%) 0.63
42 months 6951 3963 (57.0%) 2282 (32.8%) 706 (10.2%) 225 118 (52.4%) 80 (35.6%) 27 (12.0%) 0.37
69 months 6421 5059 (78.8%) 1159 (18.1%) 203 (3.16%) 210 150 (71.4%) 50 (23.8%) 10 (4.76%) 0.04
81 months 6440 5414 (84.1%) 881 (13.7%) 145 (2.25%) 216 169 (78.2%) 47 (21.8%) b 0.002
115 months 6240 5446 (87.3%) 700 (11.2%) 94 (1.51%) 205 167 (81.5%) 31 (15.1%) 7 (3.41%) 0.02
Child has difﬁculty going to sleep Child has difﬁculty going to sleep
n No Yes, not worried Yes, a bit or very worried n No Yes, not worried Yes, a bit worried
P-valuea
18 months 7230 5087 (70.4%) 1388 (19.2%) 755 (10.4%) 232 139 (59.9%) 53 (22.8%) 40 (17.2%) 0.001
30 months 6950 4275 (61.5%) 1859 (26.8%) 816 (11.7%) 219 111 (50.7%) 67 (30.6%) 41 (18.7%) 0.001
42 months 7001 4493 (64.2%) 1932 (27.6%) 576 (8.23%) 226 126 (55.8%) 64 (28.3%) 36 (15.9%) <0.001
69 months 6556 3606 (55.0%) 2356 (35.9%) 593 (9.06%) 215 89 (41.4%) 90 (41.9%) 36 (16.7%) <0.001
81 months 6560 2428 (37.0%) 3473 (52.9%) 659 (10.1%) 220 43 (19.6%) 128 (58.2%) 49 (22.3%) <0.001
115 months 6484 3119 (48.1%) 2687 (41.4%) 678 (10.5%) 212 61 (28.8%) 106 (50.0%) 45 (21.2%) <0.001
a Chi-square test (degrees of freedom ¼ 2).
b ALSPAC does not permit reporting of frequencies <5 e in this row, 47 children had 1þ night-time awakenings (<5 had 2 þ awakenings).
S.M. Collin et al. / Sleep Medicine 46 (2018) 26e3632strong evidence that difﬁculties in going to sleep were more
common at all ages in children who subsequently developed CDF
(Fig. 6, Table 2). The odds of developing CDF were 74% higher
among childrenwho had difﬁculty going to sleep (OR¼ 1.74 (95% CI
1.55e1.95) adjusted for sex and age). This association increased
over time (likelihood ratio test for interaction between difﬁculty
and time, p ¼ 0.07), from 58% higher odds at age 18 months
(OR¼ 1.58 (95% CI 1.21e2.07)) to > twofold higher odds at age nine
years (OR ¼ 2.27 (95% CI 1.68e3.06)). Among children who hadFig. 6. Difﬁculty going to sleep at age 18e115 months among children who did or did
indicate 95% CI).difﬁculties going to sleep, those whose mothers were either a bit or
very worried were 66% more likely to subsequently develop CDF
(OR ¼ 1.66 (95% CI 1.41e1.94)). Moreover, this association did not
change over time (likelihood ratio test for interaction between CDF
and time, p ¼ 0.67).
Shorter night-time sleep durations in children who subse-
quently developed CDF were mainly a consequence of later bed-
times because waking times were similar in the two groups
(Table 3, Fig. 7). Overall, children who developed CDF went to bednot develop chronic disabling fatigue (CDF) at age 13, 16 or 18 years (vertical bars
S.M. Collin et al. / Sleep Medicine 46 (2018) 26e36 3311 min later (mean difference ¼ 11.3 (95% CI 8.9 to 13.7) minutes,
adjusted for sex and age, p < 0.001) and woke two minutes later
(mean difference ¼ 2.4 (95% CI 0.5 to 4.3) minutes, adjusted for sex
and age, p ¼ 0.01).
3.2. Associations of sleep duration with CDF
3.2.1. Sleep at age nine years and CDF at age 13 years
For each additional hour of night-time sleep at age nine years,
the odds of CDF at age 13 years were 39% lower (odds ratio
(OR) ¼ 0.61 (95% CI 0.43, 0.88)) (Table 4). Mean night-time sleep
duration at age nine years was 13.9 (95% CI 3.75, 24.0) minutes
shorter among children who developed CDF at age 13 years
compared to children who did not develop CDF at this age. Effects
were similar in girls and boys, ie there was no interaction between
sex and sleep duration, andwere adjusted for multiple confounders
(see footnote to Table 4).Table 3
Childhood bedtimes and waking times (95% CI) in children with and without chronic dis
Children without CDF
Bedtime Waking time
6 months 20:08 (20:06, 20:09) 06:56 (06:54, 06:
18 months 19:45 (19:44, 19:47) 07:05 (07:03, 07:
30 months 19:49 (19:48, 19:50) 07:03 (06:59, 07:
42 months 19:45 (19:44, 19:46) 07:01 (07:00, 07:
69 months 19:52 (19:51, 19:53) 07:09 (07:08, 07:
81 months 20:03 (20:02, 20:04) 07:11 (07:10, 07:
115 months 20:50 (20:49, 20:51) 07:17 (07:17, 07:
140 months 21:21 (21:20, 21:22) 07:10 (07:10, 07:
a Based on raw (non-imputed) data e see Supplementary Table 1 for number of obser
Fig. 7. Mean bedtime and waking time at age 6e140 months among children who did o
bars indicate 95% CI).3.2.2. Sleep at age 11 years and CDF at age 16 years
For each additional hour of night-time sleep at age 11 years, the
odds of CDF at age 16 years were 51% lower (OR¼ 0.49 (95% CI 0.34,
0.70)) (Table 4). Mean night-time sleep duration at age 11 years was
18.7 (95% CI 9.08, 28.4) minutes shorter among children who
developed CDF at age 16 years compared to children who did not
develop CDF at this age. Effects were similar in girls and boys, ie
there was no interaction between sex and sleep duration, and were
adjusted for multiple confounders (see footnote to Table 4).
4. Discussion
We have shown that children who developed CDF at age 13, 16
or 18 years had shorter night-time sleep duration from age 6
months to 11 years, mainly because of later bedtimes. Differences in
the frequency of night-time awakenings were evident only at age
six months and at six, seven and nine years, but there was strongabling fatigue at age 13, 16 or 18 years.a
Children with CDF
Bedtime Waking time
57) 20:22 (20:12, 20:32) 07:01 (06:53, 07:09)
07) 19:55 (19:47, 20:03) 07:06 (07:00, 07:12)
05) 19:58 (19:50, 20:07) 07:07 (07:01, 07:12)
02) 19:50 (19:43, 19:57) 07:00 (06:54, 07:05)
10) 20:01 (19:55, 20:07) 07:12 (07:08, 07:15)
12) 20:14 (20:08, 20:20) 07:16 (07:12, 07:19)
18) 21:02 (20:56, 21:08) 07:21 (07:17, 07:24)
11) 21:34 (21:28, 21:40) 07:11 (07:08, 07:14)
vations at each age.
r did not develop chronic disabling fatigue (CDF) at age 13, 16 or 18 years (vertical
Table 4
Associations of night-time sleep duration with chronic disabling fatigue (CDF) at ages 13 and 16 years.
Raw data Imputed dataa,d
Odds ratio (95% CI) per hour of sleep Odds ratio (95% CI) per hour of sleep
CDF at 13 years, night-time sleep at 9 years Unadjusted 0.53 (0.36, 0.79) 0.53 (0.37, 0.76)
Partially adjustedb 0.52 (0.35, 0.78) 0.52 (0.36, 0.76)
Fully adjustedc e 0.61 (0.43, 0.88)
CDF at 16 years, night-time sleep at 11 years Unadjusted 0.45 (0.31, 0.65) 0.44 (0.31, 0.63)
Partially adjusted# 0.45 (0.30, 0.66) 0.44 (0.31, 0.63)
Fully adjustedc,d e 0.49 (0.34, 0.70)
a For CDF @ 13 y, auxiliary variables for themultiple imputationwere: CDF@ 13 y& 16 y; night-time sleep duration @ 7 y& 9 y; sex; BMI @ 7 y& 9 y; childmood@ 9 y (Short
Moods and Feelings Questionnaire score); maternal depression @ 6 y (Edinburgh Postnatal Depression Scale); maternal anxiety @ 6 y (Crown-Crisp Experiential Index); mean
test score for English, Mathematics and Science @ 11 y (Key Stage 2 tests); maternal life events score (antenatal); self-esteem @ 8 y (Global Self Worth subscale from Harter’s
Self Perception Proﬁle for Children); ALSPAC family adversity index (antenatal); family adversity index @8e10 y; life difﬁculties @ 11 y (Strengths and Difﬁculties Ques-
tionnaire); screen time @ 6 y; conduct problems @ 8 y; duration of breastfeeding; family income @ 4 y; maternal childhood socio-economic status; vigorous physical activity @
8 y; maternal education; maternal age at birth of child; maternal psychopathology @ 8-10 y; experienced bullying @ 8 y; days spent outdoors @ 8 y; poor concentration at
school @ 7 y; maternal and paternal BMI @ 8 y; internalising behaviour @ 4 y (Strengths and Difﬁculties Questionnaire). In a sensitivity analysis based on imputation with a
different set of (34) variables, the crude and partially adjusted odds ratios were 0.53 (0.38, 0.74) and 0.53 (0.38, 0.74), respectively.
b Adjusted for sex and family adversity index (antenatal).
c Adjusted for: sex; family adversity index (antenatal); childmood@ 9 y; conduct problems @ 8 y; duration of breastfeeding; family income@ 4 y;maternal childhood socio-
economic status; maternal life events score (antenatal); maternal depression @ 6 y; maternal anxiety @ 6 y; BMI @ 7 y& 9 y; vigorous physical activity @ 8 y; screen time @ 6 y;
experienced bullying @ 8 y; self-esteem @ 8 y; internalising behaviour @ 4 y; maternal and paternal BMI @ 8 y (see Supplementary Fig. 1).
d For CDF @ 16 y, child mood @ 10 y was substituted for mood @ 9 y, night-time sleep duration @ 9 y& 11 y was substituted for sleep duration @ 7 y& 9 y, conduct problems
@ 9 ywas substituted for conduct @ 8 y and experienced bullying @ 9 ywas substituted for experienced bullying @ 8 y (see Supplementary Fig. 2). CDF @ 18 ywas also added as
an auxiliary variable for the multiple imputations.
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common in children who subsequently developed CDF. For each
additional hour of night-time sleep at age nine years, the odds of
CDF at age 13 years were 39% lower (95% CI 12%e57% lower), and
for each additional hour at age 11 years, the odds of CDF at age 16
years were 51% lower (30%e66% lower). The mean differences in
sleep duration at age 9 and 11 years, comparing childrenwho did or
did not develop CDF at 13 and 16 years, were 14 and 19 min,
respectively. These ﬁndings suggest that sleep may play a causal
role in CFS/ME or that sleep abnormalities share a common cause
with CFS/ME.
4.1. Strengths and weaknesses
Our study is the ﬁrst to investigate a temporal relationship
between sleep and chronic disabling fatigue (as a proxy for CFS/
ME) in adolescence. The main strengths of our study are that it
used prospectively collected data from a large population-based
birth cohort and that data for exposures, outcomes and poten-
tial confounders were collected at multiple time points. Using
these data in conjunction with directed acyclic graphs enabled us
to examine temporal relationships and to adjust for known
measured confounders [22]. Furthermore, we used multiple im-
putations to adjust for higher losses to follow-up, which occur
among families experiencing greater social adversity [15]. The
identical odds ratios estimated from the raw (missing data) and
imputed datasets are indicative of little or no bias caused by dif-
ferential losses to follow-up.
The main limitation of our study is that children were not
assessed by a doctor, which is why we describe our outcome as
‘chronic disabling fatigue’, a proxy for chronic fatigue syndrome/
ME. At age 13 years, our classiﬁcation was based on parental report
of fatigue [12], whereas at age 16 years, we combined parental data
with child-completed Chalder Fatigue Questionnaire (CFQ) data
[13]. We classiﬁed children as not having CDF if they had a CFQ
score <19, a threshold which has 82.4% sensitivity and 86.4%
speciﬁcity for CFS/ME in adults [17]. Our deﬁnition of CDF did not
exclude children with comorbid depressive symptoms because
one-third of the children with CFS/ME in specialist services have
comorbid depression, and it is not yet known whether this is a
predictor of, or secondary to, CFS/ME [19].Most of the children classiﬁed with CDF at age 13 and 16 years
had been fatigued for <5 years (87%), which gives some reassurance
that the observed associations between sleep and CDF did not
reﬂect children with a long history of tiredness caused by sleep
problems. We think it unlikely that the observed differences, eg
around 10min less night-time sleep at age 9 and 11 years, indicate a
primary sleep disorder, but we did not have measurements of sleep
at older ages to conﬁrm this. Even if these relatively slight differ-
ences in sleep continued into adolescence, they would not be suf-
ﬁcient to explain chronic fatigue resulting in absence from school
or preventing the child from taking part in activities, or which was
scored 19 on the CFQ. We also excluded from our deﬁnition fa-
tigue possibly associated with snoring.
The sleep durations in our study were obtained from parents’
(mostly mothers’) answers to questions about the child’s usual
bedtime and waking time, rather than from data collected in a
sleep/wake diary or by actigraphy. We showed previously in the
same cohort that maternal anxiety had a positive association with
increased risk of CDF at age 13 years [21], and mothers who
experience anxiety might be more likely to report sleep problems
in their child. However, we adjusted for maternal anxiety in our
analysis, along with a large number (17) of other confounders. This
earlier study had shown that childhood psychological problems
and upsetting life events (before age nine years) were not associ-
ated with CDF at age 13 years after adjusting for maternal anxiety,
and we did not include childhood trauma as a potential confounder
(although confounders identiﬁed by DAG methodology included
being bullied, conduct problems and measures of self-esteem, and
internalising behaviour).
4.2. Our ﬁndings in the context of the studies
To our knowledge, all other studies to date of the relationship
between sleep and CFS/ME have focused on differences between
current patients and healthy controls. Snodgrass et al. identiﬁed
ﬁve caseecontrol and one case series study in a systematic review
of research into sleep disturbances in paediatric CFS/ME [10]. All
the studies were small (N¼ 3e57), and the only consistent ﬁndings
were of increased sleep disturbances in children with CFS/ME,
rather than differences in total sleep duration or sleep latency.
Jackson and Bruck reviewed the larger body of literature around
S.M. Collin et al. / Sleep Medicine 46 (2018) 26e36 35sleep abnormalities in adult CFS/ME patients [8]. There were few
consistent ﬁndings, other than discrepancies between subjectively
reported and objectively measured sleep, some evidence of differ-
ences in sleep stage transitions and instability, and possible
implication of heart rate variability and altered cortisol proﬁles as
underlying mechanisms.
One possible explanation for our ﬁndings is that there is a her-
itable difference in a physiological mechanism, which increases
susceptibility to CFS/ME [27] and which also affects sleep patterns
in such a way that children tend to have later bedtimes. Putative
common causes for abnormal sleep and increased CFS/ME sus-
ceptibility revolve around the hypothalamicepituitaryeadrenal
(HPA) axis function [28,29], manifesting as differences in cortisol
[30,31], adrenocorticotropic hormone [32] and melatonin [33], and
around the autonomic nervous system function, manifesting as
differences in heart rate variability [34e37].
A more direct causal hypothesis is that the children who
developed CDF had shorter sleep because they had an ‘evening
preference’ chronotype. Thus, their bedtimes were signiﬁcantly
later, and their morning waking times would have been signiﬁ-
cantly later if not constrained by school start times. Circadian
rhythmicity and sleep homeostasis are becoming increasingly
well understood and have genetic determinants. Different poly-
morphisms in the clock gene PER3 are associated with individual
morning or evening preferences [38]. These polymorphisms also
confer different abilities to cope with sleep deprivation in rela-
tion to cognitive performance [39] and vulnerability to adverse
psychological effects including mood and state anxiety in the
evening preference group [40]. On a population level, there
have been numerous reports of genetic associations between
these polymorphisms in clock genes and psychiatric disorders
(including major depressive disorder, bipolar and seasonal af-
fective disorder) [41,42].5. Conclusions and future work
We conclude that increased susceptibility to CFS/ME during
adolescence may be associated with the function of a physiological
mechanism that adversely affects sleep from a very early age.
Futurework should include detailed comparison of genetic variants
in core clock genes in CFS/ME cases compared to controls. This type
of investigation would require a large sample of clinically diag-
nosed cases but has the advantage of being able to use existing data
from population controls and to explore differences across the
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